...
search icon
gkos-img

Glaukos Corp Share Price

GKOS
NYQ
$119.53
+$2.43
(2.08%)
1D
Industry: Health Care Equipment & Supplies Sector: Health Care

Glaukos Corp Analyst Forecast

Glaukos Corp Share Price Chart

Glaukos Corp Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$6.73B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
127.73K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.70
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$73.16 L
$142.95 H
$119.53

About Glaukos Corp, Common Stock

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California. more

Industry: Health Care Equipment & SuppliesSector: Health Care

Glaukos Corp Stock Returns

Time FrameGKOSSectorS&P500
1-Week Return9.71%0.81%0.49%
1-Month Return-5.14%1.2%1.02%
3-Month Return21.36%3.24%3.34%
6-Month Return28.64%14.99%7.04%
1-Year Return-27.08%7.42%11.68%
3-Year Return133.17%20.71%71.63%
5-Year Return25.43%37.45%75.56%
10-Year Return606.7%138.53%257.55%

Glaukos Corp Financials

Dec '21Dec '22Dec '23Dec '24Dec '255YR TREND
Total Revenue294.01M282.86M314.71M383.48M507.44M[{"date":"2021-12-31","value":57.94,"profit":true},{"date":"2022-12-31","value":55.74,"profit":true},{"date":"2023-12-31","value":62.02,"profit":true},{"date":"2024-12-31","value":75.57,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Cost of Revenue66.63M68.98M75.58M94.03M224.68M[{"date":"2021-12-31","value":29.65,"profit":true},{"date":"2022-12-31","value":30.7,"profit":true},{"date":"2023-12-31","value":33.64,"profit":true},{"date":"2024-12-31","value":41.85,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Gross Profit227.38M213.88M239.14M289.45M282.76M[{"date":"2021-12-31","value":78.56,"profit":true},{"date":"2022-12-31","value":73.89,"profit":true},{"date":"2023-12-31","value":82.62,"profit":true},{"date":"2024-12-31","value":100,"profit":true},{"date":"2025-12-31","value":97.69,"profit":true}]
Gross Margin77.34%75.61%75.99%75.48%55.72%[{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.77,"profit":true},{"date":"2023-12-31","value":98.25,"profit":true},{"date":"2024-12-31","value":97.6,"profit":true},{"date":"2025-12-31","value":72.05,"profit":true}]
Operating Expenses260.26M296.20M367.84M411.82M482.36M[{"date":"2021-12-31","value":53.95,"profit":true},{"date":"2022-12-31","value":61.41,"profit":true},{"date":"2023-12-31","value":76.26,"profit":true},{"date":"2024-12-31","value":85.38,"profit":true},{"date":"2025-12-31","value":100,"profit":true}]
Operating Income(32.87M)(82.31M)(128.70M)(122.37M)(199.60M)[{"date":"2021-12-31","value":-3287200000,"profit":false},{"date":"2022-12-31","value":-8231300000,"profit":false},{"date":"2023-12-31","value":-12870000000,"profit":false},{"date":"2024-12-31","value":-12236600000,"profit":false},{"date":"2025-12-31","value":-19960000000,"profit":false}]
Total Non-Operating Income/Expense(28.48M)(27.46M)(9.50M)(22.17M)-[{"date":"2021-12-31","value":-2847900000,"profit":false},{"date":"2022-12-31","value":-2746100000,"profit":false},{"date":"2023-12-31","value":-949600000,"profit":false},{"date":"2024-12-31","value":-2217000000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Pre-Tax Income(49.27M)(98.43M)(133.73M)(145.60M)(193.04M)[{"date":"2021-12-31","value":-4926700000,"profit":false},{"date":"2022-12-31","value":-9842900000,"profit":false},{"date":"2023-12-31","value":-13372700000,"profit":false},{"date":"2024-12-31","value":-14560100000,"profit":false},{"date":"2025-12-31","value":-19304200000,"profit":false}]
Income Taxes326.00K766.00K934.00K771.00K(5.35M)[{"date":"2021-12-31","value":34.9,"profit":true},{"date":"2022-12-31","value":82.01,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":82.55,"profit":true},{"date":"2025-12-31","value":-572.91,"profit":false}]
Income After Taxes(49.59M)(99.19M)(134.66M)(146.37M)-[{"date":"2021-12-31","value":-4959300000,"profit":false},{"date":"2022-12-31","value":-9919500000,"profit":false},{"date":"2023-12-31","value":-13466100000,"profit":false},{"date":"2024-12-31","value":-14637200000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Continuous Operations(49.59M)(99.19M)(134.66M)(146.37M)-[{"date":"2021-12-31","value":-4959300000,"profit":false},{"date":"2022-12-31","value":-9919500000,"profit":false},{"date":"2023-12-31","value":-13466100000,"profit":false},{"date":"2024-12-31","value":-14637200000,"profit":false},{"date":"2025-12-31","value":"-","profit":true}]
Income From Discontinued Operations-----[{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true},{"date":"2025-12-31","value":"-","profit":true}]
Net Income(49.59M)(99.19M)(134.66M)(146.37M)(187.69M)[{"date":"2021-12-31","value":-4959300000,"profit":false},{"date":"2022-12-31","value":-9919500000,"profit":false},{"date":"2023-12-31","value":-13466100000,"profit":false},{"date":"2024-12-31","value":-14637200000,"profit":false},{"date":"2025-12-31","value":-18769100000,"profit":false}]
EPS (Diluted)(0.84)(2.19)(2.27)(1.90)(0.90)[{"date":"2021-12-31","value":-84,"profit":false},{"date":"2022-12-31","value":-219,"profit":false},{"date":"2023-12-31","value":-227,"profit":false},{"date":"2024-12-31","value":-190,"profit":false},{"date":"2025-12-31","value":-90,"profit":false}]

Glaukos Corp Ratios

Glaukos Corp Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

GKOS
Cash Ratio 2.75
Current Ratio 4.69
Quick Ratio 4.06

Glaukos Corp Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

GKOS
ROA (LTM) -13.35%
ROE (LTM) -26.38%

Glaukos Corp Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

GKOS
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.73

Glaukos Corp Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

GKOS
Trailing PE NM
Forward PE 2000.00
P/S (TTM) 13.70
P/B 8.17
Price/FCF NM
EV/R 13.02
EV/Ebitda NM
PEG 1.64

FAQs

What is Glaukos Corp share price today?

Glaukos Corp (GKOS) share price today is $119.53

Can Indians buy Glaukos Corp shares?

Yes, Indians can buy shares of Glaukos Corp (GKOS) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GKOS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Glaukos Corp be purchased?

Yes, you can purchase fractional shares of Glaukos Corp (GKOS) via the Vested app. You can start investing in Glaukos Corp (GKOS) with a minimum investment of $1.

How to invest in Glaukos Corp shares from India?

You can invest in shares of Glaukos Corp (GKOS) via Vested in three simple steps:

  • Click on Sign Up or Invest in GKOS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Glaukos Corp shares
What is Glaukos Corp 52-week high and low stock price?

The 52-week high price of Glaukos Corp (GKOS) is $142.95. The 52-week low price of Glaukos Corp (GKOS) is $73.16.

What is Glaukos Corp price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Glaukos Corp (GKOS) is

What is Glaukos Corp price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Glaukos Corp (GKOS) is 8.17

What is Glaukos Corp dividend yield?

The dividend yield of Glaukos Corp (GKOS) is 0.00%

What is the Market Cap of Glaukos Corp?

The market capitalization of Glaukos Corp (GKOS) is $6.73B

What is Glaukos Corp's stock symbol?

The stock symbol (or ticker) of Glaukos Corp is GKOS

How Can Investors Use Glaukos Corp Share Price Data for Long-Term Investment Decisions?

Consider the share price of Glaukos Corp as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Glaukos Corp has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Glaukos Corp shares for Indian investors?

When investing in Glaukos Corp shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Glaukos Corp stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Glaukos Corp share price with other stocks in the same sector?

Rather than merely checking the share price of Glaukos Corp and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Glaukos Corp stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top